The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.

Muscarinic M1 preferring agonists may improve cognitive deficits associated with Alzheimer's disease. Side effect assessment of the M1 preferring agonist WAY-132983 showed significant salivation (10 mg/kg i.p. or p.o.) and produced dose-dependent hypothermia after i. p. or p.o. administration. WAY-132983 significantly reduced scopolamine (0.3 mg/kg i.p.)-induced hyperswimming in mice. Cognitive assessment in rats used pretrained animals in a forced choice, 1-h delayed nonmatch-to-sample radial arm maze task. WAY-132983 (0.3 mg/kg i.p) significantly reduced scopolamine (0.3 mg/kg s.c.)-induced errors. Oral WAY-132983 attenuated scopolamine-induced errors; that is, errors produced after combining scopolamine and WAY-132983 (to 3 mg/kg p.o.) were not significantly increased compared with those of vehicle-treated control animals, whereas errors after scopolamine were significantly higher than those of control animals. With the use of miniosmotic pumps, 0.03 mg/kg/day (s.c.) WAY-132983 significantly reduced AF64A (3 nmol/3 microliter/lateral ventricle)-induced errors. Verification of AF64A cholinotoxicity showed significantly lower choline acetyltransferase activity in the hippocampi of AF64A-treated animals, with no significant changes in the striatal or frontal cortex. Cognitive assessment in primates involved the use of pretrained aged animals in a visual delayed match-to-sample procedure. Oral WAY-132983 significantly increased the number of correct responses during short and long delay interval testing. These effects were also apparent 24 h after administration. WAY-132983 exhibited cognitive benefit at doses lower than those producing undesirable effects; therefore, WAY-132983 is a potential candidate for improving the cognitive status of patients with Alzheimer's disease.

Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling.

Rational drug design utilizing a receptor homology model of the human muscarinic M1 receptor led to the discovery of the highly potent (Ki = 2 nM), efficacious, and in vivo functionally-selective M1 agonist, WAY-132983.

Arecoline via miniosmotic pump improves AF64A-impaired radial maze performance in rats: a possible model of Alzheimer's disease.

Male Sprague-Dawley rats, preoperatively trained in a 1-h delay non-match-to-position radial maze task, received bilateral stereotaxic injections of a selective cholinotoxin, ethylcholine aziridinium ion (AF64A: 3 nmol/3 microliters/lateral ventricle). Animals treated with AF64A made significantly more total postdelay errors than vehicle controls. Sustained delivery, via miniosmotic pumps, of arecoline (0.1, 0.3, 1, 3, 10, or 30 mg/kg/day sc for 14 days) attenuated the AF64A-induced cognitive impairment in a dose-dependent manner, producing an inverted U-shaped dose-response function which was optimal at 1.0 mg/kg/day. Following these studies, choline acetyltransferase activity was significantly reduced in hippocampi extracted from the AF64A-treated rats, indicating successful cholinotoxicity. This paradigm may be useful as a possible screen for potential Alzheimer's disease therapeutic agents. This conclusion is supported by published reports of beneficial arecoline effects observed following 2-week intravenous infusions in patients with Alzheimer's disease (Soncrant, Raffaele, Asthana, Berardi, Morris, & Haxby, 1993).

Task difficulty determines the differential memory-impairing effects of EAA antagonists in gerbils.

Excitatory amino acid antagonists (EAAAs) have been shown to disrupt learning and memory in a variety of cognitive tasks. EAAAs have been reported to produce differential effects on working memory (WM) and reference memory (RM) or to have no effect at all. Apparent selective effects of EAAAs on WM and/or RM may have been due to differences between the effects of competitive and noncompetitive EAAAs, dose selection, or to different task requirements for the WM and RM components. In the present experiments, we assessed the effects of a noncompetitive EAAA (MK-801), a competitive EAAA (CPP), and the muscarinic antagonist scopolamine in two cognitive tasks, the split-stem T-maze and the eight-arm radial maze. In these two tasks, the WM and the RM components differed in their relative degree of difficulty. Gerbils were trained on either the T-maze, where WM was more difficult than RM, or on the radial arm maze, where RM was more difficult than WM. In the T-maze, MK-801 (0.1 mg/kg, IP, 30 min prior), CPP (30.0 mg/kg, IP, 2 h prior) and scopolamine (0.3 mg/kg, IP, 30 min prior) impaired both WM and RM, but the magnitude of the impairing effect was statistically greater for the WM component, the more difficult of the two components. Lower doses of these three compounds produced either selective effects on WM or no effect at all. In the radial arm maze all three drugs impaired both components, but the magnitude of the impairing effect was statistically greater for the RM component, the more difficult of the two components.(ABSTRACT TRUNCATED AT 250 WORDS)

Neuroprotection by MK-801 in temperature maintained gerbils.

Hypothermia reduces ischemic brain damage, confounding interpretation of the neuroprotective effects of drugs. Specifically, the neuroprotectant MK-801 has been shown to cause hypothermia. Some have claimed that when body temperature is maintained, MK-801 is not a neuroprotectant, whereas others claim it retains its neuroprotective activity. MK-801 was evaluated for neuroprotective properties in free-regulating as well as temperature-maintained gerbils receiving 5 or 10 min of bilateral carotid occlusion. After 10 min of ischemia, free-regulating animals exhibited significant hypothermia (as low as 32 degrees C) and showed significant neuroprotection after 3 mg/kg IP MK-801. When a hyperthermic body temperature (38.5 degrees C) was maintained, no reduction in brain damage was evident after up to 10 mg/kg IP MK-801, even when occlusion time was reduced to 5 min. However, when a normothermic body temperature (36.5 degrees C) was maintained, 10 mg/kg IP MK-801 significantly reduced brain damage after 5 min of ischemia. Thus, although a higher dose of the drug is required, MK-801 can reduce ischemic brain damage in the absence of hypothermia. The need for this high dose suggests that mechanisms other than NMDA receptor complex antagonism may be involved in the neuroprotective actions of MK-801.

Biochemical and behavioral characterization of a novel cholinergic agonist, SR 95639.

Selective M1 cholinergic agonists may be useful in treating dementias due to cholinergic hypofunction. SR 95639 has recently been described as such a compound. We found the compound to have affinity for M1 sites (Ki = 2.1 microM) which was approximately 3-fold higher than its affinity for M2 sites. Functional partial agonism was suggested by an inconsistent increase in phosphoinositide (PI) turnover in rat hippocampal slices, combined with blockade of carbachol-stimulated PI turnover. In vivo M2-mediated effects were absent. Scopolamine-induced hyperactivity was attenuated by SR 95639 and scopolamine-impaired inhibitory avoidance and radial maze performance were improved. The compound appears to be a weakly selective M1 partial agonist with potential advantages over existing compounds.

CGS 19755: a novel competitive N-methyl-D-aspartate (NMDA) receptor antagonist with anticonvulsant, anxiolytic and anti-ischemic properties.

CGS 19755 is a potent and selective competitive antagonist at NMDA receptors in the brain. In preclinical animal tests, the compound produces anticonvulsant, anxiolytic and anti-ischemic effects. CGS 19755 is not very active when administered orally, and intravenous administration is the most practical for clinical application. The anti-ischemic potential of CGS 19755 provides the most attractive application for clinical investigation.

Behavioral tolerance and sensitization to CGS 19755, a competitive N-methyl-D-aspartate receptor antagonist.

Competitive N-methyl-D-aspartate (NMDA) receptor antagonists, including CGS 19755, have the ability to antagonize NMDA-induced convulsions, to cause ataxia and, at high doses, to increase spontaneous locomotor activity. It was of interest to determine whether or not repeated treatment with CGS 19755 would induce tolerance to some or all of these effects. CGS 19755 was administered to mice twice daily for 14 days at 54 mg/kg i.p. per injection. One day after the last repeated injection, mice were challenged with vehicle or one of several doses of CGS 19755 (10, 30, 54 and 100 mg/kg) and were tested for evidence of motor impairment (using righting reflex and traction tests), for spontaneous locomotor activity and for the threshold dose of NMDA required to induce convulsions. When challenged with CGS 19755, mice that had previously received only vehicle showed reduced motor activity in response to doses of 54 and 100 mg/kg. In contrast, mice that had received the repeated treatment regimen of CGS 19755 increased motor activity in response to challenge doses of 30 and 54 mg/kg. These effects resembled those reported previously by some investigators for phencyclidine. However, repeated treatment with CGS 19755 induced only slight tolerance to the ability of this drug to cause ataxia. In mice treated repeatedly with CGS 19755, the threshold dose of NMDA to induce convulsions did not differ significantly from that in mice treated repeatedly with vehicle, indicating no demonstrable tolerance to the apparent anticonvulsant effects of CGS 19755 over this time period.(ABSTRACT TRUNCATED AT 250 WORDS)

Motor activity changes following cerebral ischemia in gerbils are correlated with the degree of neuronal degeneration in hippocampus.

Cerebral ischemia was induced in Mongolian gerbils by bilateral occlusion of the carotid arteries. Subsequent histological assessment revealed neuronal degeneration in the CA1 area of the hippocampus. A functional behavioral change was reflected in an elevation of motor activity compared with sham-operated animals. The degree of hippocampal damage was positively correlated with the increase in motor activity. It is concluded that alterations in both measures result from the interruption of blood flow to the brain but may be brought about by different mechanisms.

The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils.

N-Methyl-D-aspartate (NMDA) antagonists reduce ischemic brain damage and associated hypermotility. Two potent, selective and competitive NMDA antagonists, cis-4-(phosphonomethyl)-2-piperidine-carboxylic acid (CGS 19755) and 4-(3-phosphonopropyl)-2-piperazine-carboxylic acid (CPP), were characterized in the gerbil ischemia model with respect to dose-response and time course effects. Both drugs were effective in reducing ischemia-induced hippocampal brain damage as well as hypermotility. In this model, CGS 19755 was more potent than CPP, and had protective effects when given after longer delays between ischemia and drug administration.

The novel N-methyl-D-aspartate (NMDA) antagonist CGS 19755 prevents ischemia-induced reductions of adenosine A1, NMDA, and PCP receptors in gerbil brain.

Transient brain ischemia results in a selective destruction of cell bodies within the hippocampus and cortex. This cellular destruction appears to be mediated through a release of endogenous exictatory amino acids following the ischemic episode, since the neurotoxic effects of ischemia can be attenuated by compounds that have antagonist activity at N-methyl-D-aspartate (NMDA) receptors. In the present study, the protective effects of a novel NMDA receptor antagonist, CGS 19755, were further evaluated by using quantitative autoradiography to characterize adenosine A1, NMDA, PCP, and benzodiazepine receptors in ischemic gerbil brain. Bilateral carotid artery occlusion (20 minutes) resulted in marked decreases (30-60%) in adenosine A1, NMDA, and PCP, but not benzodiazepine, receptors in gerbil forebrain. Postischemic treatment with CGS 19755 was found to completely block the ischemia-induced decreases in brain adenosine and NMDA receptors. [3H]TCP binding in ischemic gerbil brain was also elevated by CGS 19755 treatment; significant differences remained, however, between the CGS 19755-treated and control gerbils. These results indicate that transient brain ischemia produces significant and selective alterations in gerbil forebrain receptor systems. The observed decreases in radioligand binding are probably reflective of an ischemia-induced destruction of forebrain structures. However, there is some evidence that transient ischemia can also cause long-term changes in the affinity of some receptor systems. The postischemic efficacy of CGS 19755 appears to be due to its ability to block the neurotoxic effects of transient ischemia.

Characterization of motor activity patterns induced by N-methyl-D-aspartate antagonists in gerbils.

A computerized motor activity data collection and analysis system is described. An example of the utilization of the Digiscan system is provided, in which motor activity patterns induced by three N-methyl-D-aspartate (NMDA) antagonists and the dissociative anesthetic, ketamine, are compared. All of these compounds produce a distinct pattern of motor activity characterized by an increase in distance traveled, movement time, speed and perimeter walking, with a decrease in vertical activity. Recently described links between NMDA and phencyclidine (PCP) binding sites may account for these findings. The utility of computerized motor activity apparatus is clearly demonstrated.

Lack of tolerance or withdrawal effects in mice after chronic administration of the non-sedating anxiolytic, CGS 9896.

CGS 9896, a non-sedating anxiolytic, was compared to diazepam with respect to the development of tolerance and withdrawal. Both compounds were administered daily to mice at various doses (3, 10 or 30 mg/kg) for periods of up to 4 weeks. Measures of sedation/muscle relaxation, motor activity and anticonvulsant effects were then assessed. When administered acutely, CGS 9896 increased motor activity, had no effect on traction reflex, and elevated the threshold for PTZ-induced convulsions. After chronic administration of CGS 9896, no changes in these parameters were observed compared to the effects seen after acute treatment. Acute administration of diazepam reduced motor activity, impaired traction reflex and increased PTZ-induced convulsion threshold. Tolerance developed to the effects of diazepam in all three measures. Following a four week dosing period with 30 mg/kg of either CGS 9896 or diazepam, the drugs were withdrawn and similar behavioral measures obtained at various withdrawal intervals up to 15 days. In separate groups of mice, precipitated withdrawal was also assessed by the administration of the benzodiazepine agonist, CGS 8216. No effects were observed after any period of withdrawal from CGS 9896. By contrast, withdrawal from diazepam resulted in significant alterations of motor activity and convulsion threshold. These results indicate that CGS 9896 is likely to be free of undesirable tolerance and withdrawal effects typically associated with the benzodiazepines.

CGS 8216 and CGS 9896, novel pyrazoloquinoline benzodiazepine ligands with benzodiazepine agonist and antagonist properties.

CGS 8216 and CGS 9896 are two recently described compounds which interact with benzodiazepine binding sites but have pharmacological, biochemical and behavioral characteristics which distinguish them from classical benzodiazepines. CGS 8216 shows properties of a weak inverse agonist, while CGS 9896 shows properties of a mixed agonist/antagonist. Experiments using quantitative autoradiography to determine benzodiazepine binding site interactions of these compounds in discrete anatomical areas are described. Results indicate that [3H]-CGS 8216 does not show any regional differentiation in binding characteristics in 7 brain areas studied. CGS 9896 preferentially inhibited [3H]-flunitrazepam from cerebellar sites compared to hippocampal dentate gyrus sites, but the magnitude of this effect was small. These data support the conclusion that CGS 9896 is acting preferentially at putative benzodiazepine type 1 sites and is consistent with the mixed agonist/antagonist profile of the compound.

The neuropharmacology of various diazepam antagonists.

Recently, compounds which bind avidly to benzodiazepine binding sites have been shown to possess diazepam antagonist properties. For example, the benzodiazepine RO 15-1788 and the pyrazoloquinoline CGS 8216 can antagonize the anxiolytic, sedative, muscle relaxant and anticonvulsant properties of diazepam. The beta-carbolines have also been shown to antagonize several actions of diazepam. Other compounds including physostigmine, naloxone, bicuculline, picrotoxin, caffeine and theophylline, lack appreciable affinity for benzodiazepine binding sites but do antagonize at least some of the behavioral actions of diazepam. Their antagonist properties are probably the result of opposing pharmacological actions rather than direct receptor antagonism. Clinically, a potent safe diazepam antagonist could be used to reverse effects of diazepam overdose and to speed recovery of diazepam-treated patients after various out-patient procedures.

Ethanol dependence in the rat: role of non-specific and limbic regions in the withdrawal reaction.

Chronic bipolar electrodes were implanted in cortical, limbic, diencephalic and mesencephalic regions of the rat. Following recovery from surgery the rats were maintained for 14--26 days on a liquid diet in which 35--42% of total calories were provided by ethanol. Following ethanol withdrawal, electrographic and behavioral monitoring was continued for 8--10 h. The withdrawal of ethanol resulted in the time-dependent appearance of a variety of withdrawal signs including tail arching, ataxia, rigidity, tremor and spontaneous and audiogenic convulsions. These behavioral signs were accompanied by the development of epileptiform abnormalities across wide-spread brain regions. Analysis of preconvulsive spike activity revealed a greater spike frequency in limbic, mesencephalic and non-specific diencephalic regions, as compared to those in cortex and specific diencephalon. Seizure discharge during the tonic-clonic phase of the primary audiogenic convulsion was initiated in the mesencephalon or amygdala, but spread rather extensively to the remainder of the brain. In those instances, however, where multiple convulsions occurred following the audiogenic convulsions, there was a marked decline in spread of seizure discharge to the cortex. These results were interpreted to support the notion that some degree of neuroanatomical specificity exists in the genesis of epileptiform abnormalities during ethanol withdrawal. A comparison of these results with those studying the neural mechanisms underlying other forms of generalized epilepsy was made. It is hypothesized that central pacemaking regions such as medial thalamus or reticular formation may serve to organize isolated epileptiform activity into coherent patterns of paroxysmal activity throughout the brain during the ethanol withdrawal syndrome.